. 2016 Jul 30;7(35):57036–57049. doi: 10.18632/oncotarget.10958

Table 5. Elapsed time to achieve partial remission in half of patients (PR₅₀) according to the mutational status of JAK2 and CALR.

Characteristics	JAK2+/CALR+ (A)	JAK2+/CALR- (B)	JAK2-/CALR+ (C)	JAK2-/CALR- (D)
Elapsed time to PR₅₀, months (95% CI)	28.5 (17–N/A)	14 (12–27)	56 (21–N/A)	20 (10–N/A)

CI, confidence interval; N/A, not applicable

Table 5. Elapsed time to achieve partial remission in half of patients (PR50) according to the mutational status of JAK2 and CALR.